Cost of skeletal-related events in European patients with solid tumours and bone metastases: Data from a prospective multinational observational study

Journal of Medical Economics

Volumn 16, Issue 5, 2013, Pages 691-700

  Hechmati, G ^a   Cure, S ^b   Gouepo A ^b   Hoefeler, H ^c   Lorusso, V ^d,e   Luftner D ^f   Duran, I ^g,h   Garzon Rodriguez, C ⁱ   Ashcroft, J ^j   Wei, R ^a   Ghelani, P ^k   Bahl, A ^a,l  

^a AMGEN INC   (United States)

^b OPTUM   (United States)

^c Forschungszentrum Ruhr Witten   (Germany)

^d ASL Lecce   (Italy)

^e NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g Gynecolog ical and Genitourinary Tumors Programme Centro Integra Oncologico Clara Campal CIOCC   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^j PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

^k Biostatistics   (United Kingdom)

^l UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

Bone metastasis; Cost; Healthcare resource; Skeletal related event; Solid tumour

Indexed keywords

ADULT; ARTICLE; BONE METASTASIS; COST BENEFIT ANALYSIS; EUROPEAN AMERICAN; FEMALE; FOLLOW UP; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HUMAN; ITALY; LENGTH OF STAY; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OBSERVATIONAL STUDY; ORTHOPEDIC SURGERY; OUTPATIENT CARE; PATHOLOGIC FRACTURE; RADIATION; SOLID TUMOR; SPAIN; SPINAL CORD COMPRESSION; UNITED KINGDOM;

BONE NEOPLASMS; COSTS AND COST ANALYSIS; EUROPE; FRACTURES, BONE; HEALTH SERVICES; HUMANS; LENGTH OF STAY; MULTICENTER STUDIES AS TOPIC; NEOPLASM METASTASIS; ORTHOPEDIC PROCEDURES; OSTEORADIONECROSIS; PROSPECTIVE STUDIES; SPINAL CORD COMPRESSION; WOUNDS AND INJURIES;

EID: 84876385744     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.779921     Document Type: Article

References (20)

1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76 (Pubitemid 32452017)
2. Rubens RD. Bone metastases - the clinical problem. Eur J Cancer 1998;34:210-3 (Pubitemid 28189188)
3. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s (Pubitemid 44703797)
4. Katzer A, Meenen NM, Grabbe F, et al. Surgery of skeletal metastases. Arch Orthop Trauma Surg 2002;122:251-8
5. Loblaw DA, Wu JS, Kirkbride P, et al. Pain flare in patients with bone metastases after palliative radiotherapy - a nested randomized control trial. Support Care Cancer 2007;15:451-5 (Pubitemid 46697018)
6. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84 (Pubitemid 40613323)
7. Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletalrelated events in patients with bone metastases from lung cancer. Oncology 2004;67:390-6
8. Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006;4:341-7 (Pubitemid 44420137)
9. Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317-22
10. Pockett RD, Castellano D, McEwan P, et al. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care 2010;19:755-60
11. Hechmati G, Hoefeler H, Bahl A, et al. Skeletal-related events in patients with bone metastases lead to considerable health resource utilisation in Europe: analysis of a multinational observational study. Value Health 2011;14:A168
12. National Institute of Clinical Excellence (NICE). Advanced breast cancer: diagnosis and treatment. Full Guideline. 2009. London: NICE. http://guidance.nice.org.uk/CG81/Guidance/pdf/English. Accessed July 5, 2012
13. National Institute of Clinical Excellence (NICE). The diagnosis and treatment of lung cancer (update). Full Guideline. 2011. London: NICE. http://guidance.nice.org.uk/CG121/Guidance/pdf/English. Accessed July 5, 2012
14. National Institute of Clinical Excellence (NICE). Metastatic spincal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression. Full Guideline. 2008. London: NICE. http://guidance.nice.org.uk/CG75/Guidance/pdf/English. Accessed July 5, 2012
15. Saad F, McKiernan J, Eastham J. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol 2006;24:4-12 (Pubitemid 43097349)
16. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21 (Pubitemid 38715767)
17. Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48:3082-92
18. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21
19. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21: 3150-7 (Pubitemid 46606297)
20. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst 2004;96:879-82 (Pubitemid 38807610)